Clinical data
Trade names Myrbetriq (US), Betanis (JP), Betmiga (EU, RU)
License data
  • US: C (Risk not ruled out)
Routes of
Oral (tablets)
ATC code G04BD12 (WHO)
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 29–35%[1]
Protein binding 71%[1]
Metabolism Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase[1]
Biological half-life 50 hours[1]
Excretion Urine (55%), faeces (34%)[1]
Synonyms YM-178
CAS Number 223673-61-8
PubChem (CID) 9865528
ChemSpider 8041219
ECHA InfoCard 100.226.392
Chemical and physical data
Formula C21H24N4O2S
Molar mass 396.506 g/mol
3D model (Jmol) Interactive image

Mirabegron (trade name Myrbetriq meer-BET-trick in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder.[2] It was developed by Astellas Pharma and was approved in the United States in July 2012.[3]

Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.[4]

Medical uses

Its primary use is in the treatment of overactive bladder.[1][5][6]

Mirabegron has also recently been shown to activate brown fat and increase metabolism. In a small study of 15 healthy, lean men, Mirabegron was shown to increase basal heart rate, metabolic rate and blood pressure which are signs of cardiovascular stimulation.[7]

Recently, mirabegron was shown to relax in vitro human and rabbit prostate smooth muscle through activation of β3 adrenoceptor.[8] The same group also showed that mirabegron promotes smooth muscle relaxation by α1 adrenergic receptor blockade.[9]

Adverse effects

Adverse effects by incidence:[1][5][6]

Very common (>10% incidence) adverse effects include:

Common (1–10% incidence) adverse effects include:

Rare (<1% incidence) adverse effects include:


  1. 1 2 3 4 5 6 7 "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.
  2. Gras, J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998). 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458.
  3. Sacco, E; Bientinesi, R; et al. (Apr 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opin Drug Discov. 9 (4): 433–48. doi:10.1517/17460441.2014.892923. PMID 24559030.
  4. "New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)". ChEMBL. 5 July 2012. Retrieved 28 September 2012.
  5. 1 2 "MYRBETRIQ (mirabegron) tablet, film coated, extended release [Astellas Pharma US, Inc.]". DailyMed. Astellas Pharma US, Inc. September 2012. Retrieved 17 November 2013.
  6. 1 2 "Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Retrieved 17 November 2013.
  7. Cypess, Aaron; Weiner, Lauren; Roberts-Toler, Carla; Elía, Elisa; Kessler, Skyler; Kahn, Peter; English, Jeffrey; Chatman, Kelly; Trauger, Sunia; Doria, Alessandro; Kolodny, Gerald (6 January 2015). "Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist". Cell Metabolism. 21 (1): 33–38. doi:10.1016/j.cmet.2014.12.009. PMID 25565203.
  8. Calmasini, F. B., T. Z. Candido, E. C. Alexandre, C. A. D'Ancona, D. Silva, M. A. de Oliveira, G. De Nucci, E. Antunes and F. Z. Monica (2015). "The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?" Prostate 75(4): 440-447.
  9. Alexandre, E C; Kiguti, L R; Calmasini, F B; Silva, F H; da Silva, K P; Ferreira, R; Ribeiro, C A; Mónica, F Z; Pupo, A S (2015-10-01). "Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade". British Journal of Pharmacology: n/a–n/a. doi:10.1111/bph.13367. ISSN 1476-5381.
This article is issued from Wikipedia - version of the 11/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.